Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

PYXS | Pyxis Oncology Inc

Index	-	P/E	-	EPS (ttm)	-2.84	Insider Own	30.80%	Shs Outstand	34.96M	Perf Week	0.00%
Market Cap	81.60M	Forward P/E	-	EPS next Y	-1.65	Insider Trans	-0.09%	Shs Float	30.36M	Perf Month	-13.89%
Income	-98.92M	PEG	-	EPS next Q	-0.54	Inst Own	21.79%	Short Float / Ratio	3.16% / 4.62	Perf Quarter	-24.39%
Sales	0.00M	P/S	-	EPS this Y	43.05%	Inst Trans	-2.20%	Short Interest	0.96M	Perf Half Y	-31.11%
Book/sh	3.69	P/B	0.50	EPS next Y	20.49%	ROA	-47.35%	Target Price	9.75	Perf Year	-3.63%
Cash/sh	3.29	P/C	0.57	EPS next 5Y	-	ROE	-55.38%	52W Range	1.10 - 6.92	Perf YTD	38.81%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-59.59%	52W High	-73.12%	Beta	1.16
Dividend %	-	Quick Ratio	16.18	Sales past 5Y	0.00%	Gross Margin	-	52W Low	69.09%	ATR	0.18
Employees	75	Current Ratio	16.18	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	40.33	Volatility	13.14% 9.31%
Optionable	Yes	Debt/Eq	0.15	EPS Q/Q	47.42%	Profit Margin	-	Rel Volume	0.79	Prev Close	1.78
Shortable	Yes	LT Debt/Eq	0.14	Earnings	Aug 11 BMO	Payout	-	Avg Volume	207.59K	Price	1.86
Recom	1.40	SMA20	-10.40%	SMA50	-18.82%	SMA200	-22.41%	Volume	164,070	Change	4.49%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-05-23	Initiated	RBC Capital Mkts	Outperform	$7
Nov-02-21	Initiated	Jefferies	Buy	$25
Nov-02-21	Initiated	Credit Suisse	Outperform	$19
Nov-02-21	Initiated	BofA Securities	Neutral	$16

Sep-14-23 05:03PM	Insider Sell: President and CEO Lara Sullivan Sells 27,917 Shares of Pyxis Oncology Inc (GuruFocus.com)
Aug-31-23 04:01PM	Pyxis Oncology to Participate in Two Upcoming Investment Conferences (GlobeNewswire)
Aug-23-23 08:35AM	Pyxis Oncology Successfully Completes Acquisition of Apexigen (GlobeNewswire)
Aug-11-23 07:00AM	Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update (GlobeNewswire) +6.61%
Aug-01-23 04:01PM	Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference (GlobeNewswire)
05:00PM	Loading…
Jun-30-23 05:00PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-23 08:30AM	Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs (GlobeNewswire)
May-24-23 06:45AM	Pyxis Oncology to Acquire Apexigen (GlobeNewswire) -10.46%
May-11-23 07:00AM	Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Mar-31-23 05:00PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -33.17%
Mar-30-23 02:16PM	Pyxis Stock Is Up 170% This Week. How Much Higher Can It Go? (TipRanks) +32.16%
Mar-22-23 06:45AM	Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update (GlobeNewswire)
Mar-16-23 07:30AM	Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors (GlobeNewswire) +7.46%
Feb-13-23 08:00AM	Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference (GlobeNewswire)
Dec-23-22 04:45PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.79%
06:45AM	Loading…
Dec-01-22 06:45AM	Pyxis Oncology Announces FDA Clearance of Two IND Applications (GlobeNewswire)
Nov-01-22 06:30AM	Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update (GlobeNewswire) -9.63%
Sep-30-22 05:00PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-22 07:00AM	Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update (GlobeNewswire)
Jul-12-22 06:45AM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-28-22 06:35AM	Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference (GlobeNewswire)
Jun-21-22 10:40AM	Great news for Pyxis Oncology, Inc. (NASDAQ:PYXS): Insiders acquired stock in large numbers last year (Simply Wall St.)
May-19-22 06:35AM	Pyxis Oncology Announces Presentations at Upcoming Investor Conferences (GlobeNewswire)
May-13-22 08:03AM	Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update (GlobeNewswire) -9.01%
May-07-22 10:34AM	Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely? (Simply Wall St.)
Apr-27-22 06:35AM	Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference (GlobeNewswire)
Apr-13-22 06:35AM	Pyxis Oncology Announces Leadership Changes (GlobeNewswire)
Apr-08-22 01:05PM	Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-29-22 11:00AM	Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology (PR Newswire)
06:35AM	Pyxis Oncology Provides Corporate and Financial Update (GlobeNewswire)
06:35AM	Loading…
Mar-22-22 06:35AM	Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022 (GlobeNewswire) -8.04%
Jan-10-22 11:17AM	Quite a few insiders invested in Pyxis Oncology, Inc. (NASDAQ:PYXS) last year which is positive news for shareholders (Simply Wall St.)
Dec-15-21 08:00AM	Pyxis to be Added to Russell 2000® Index (GlobeNewswire)
Dec-09-21 08:30AM	Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer (GlobeNewswire)
Nov-15-21 07:15AM	Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update (GlobeNewswire)
Nov-10-21 08:00AM	Pyxis Oncology to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-08-21 03:31PM	Pyxis Oncology well positioned to advance its work against cancer amid public debut: CEO (Yahoo Finance Video)
Oct-07-21 10:24PM	Pyxis Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Connealy Pamela Ann	CFO and COO	Sep 25	Buy	1.67	12,000	20,044	804,106	Sep 25 05:04 PM
Wadhane Jitendra	Chief Accounting Officer	Sep 25	Buy	1.77	5,000	8,850	224,437	Sep 25 05:05 PM
Connealy Pamela Ann	CFO and COO	Sep 22	Buy	1.74	5,000	8,695	792,106	Sep 22 07:34 PM
Wadhane Jitendra	Chief Accounting Officer	Sep 22	Buy	1.74	2,500	4,349	219,437	Sep 22 07:35 PM
Sullivan Lara	President and CEO	Sep 18	Sale	2.10	8,541	17,936	2,403,882	Sep 18 07:03 PM
Sullivan Lara	President and CEO	Sep 14	Sale	2.25	100	225	2,412,423	Sep 18 07:03 PM
Sullivan Lara	President and CEO	Sep 13	Sale	2.27	3,000	6,816	2,597,265	Sep 13 08:16 PM
Sullivan Lara	President and CEO	Sep 12	Sale	2.25	4,917	11,071	2,600,265	Sep 13 08:16 PM
Sullivan Lara	President and CEO	Sep 11	Sale	2.27	20,000	45,414	2,605,182	Sep 13 08:16 PM
PFIZER INC	10% Owner	Mar 17	Buy	2.76	1,811,594	4,999,999	5,952,263	Mar 21 06:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PYXS | Pyxis Oncology Inc

Upgrade your FINVIZ experience